Board Chair and former Executive Chairman · Lyell Immunopharma, Inc. (LYEL)

Richard Klausner

A named executive officer of Lyell Immunopharma in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$33,366,629

Salary $253,549Stock awards $10,908,331Bonus $222,007

FY2020: $38,852,236

1st of 4 named executive officers at Lyell Immunopharma by FY2021 total.

4 named officers on file for Lyell Immunopharma, FY2021

Richard Klausner’s pay file — $29

  • 2 fiscal years of pay, line by line
  • LYEL’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lyell Immunopharma’s whole pay program stands against its peers

  • Lyell Immunopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LYEL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Richard Klausner’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Richard Klausner compensation by year

Lyell Immunopharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as Lyell Immunopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$427,147$253,549
Bonus$738,712$222,007
Stock awards$20,799,288$10,908,331
Option awards$16,618,943$21,948,133
Non-equity incentive$261,288$0
Pension and deferred compensation$0$0
All other$6,858$34,609
Total$38,852,236$33,366,629

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lyell Immunopharma, Inc. DEF 14A filed April 28, 2022, accession 0001140361-22-016525, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Lyell Immunopharma, Inc. filed document, accession 0001140361-22-016525. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

$38.9M
$33.4M
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU1,166,667$9,030,003—
Option352,083—$3.65

Per the Outstanding Equity Awards at Fiscal Year-End table in Lyell Immunopharma, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2021 proxy (filed April 28, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-10Grant or award derivative—9,250$0.009,250
2025-05-15Grant or award derivative—130,000$0.00130,000
2025-03-14Purchase—158,000$0.60843,365

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Lyell Immunopharma’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Richard Klausner · this pageBoard Chair and former Executive Chairman$33,366,629
Charles NewtonChief Financial Officer$20,124,792
Elizabeth HomansChief Executive Officer$18,643,569
Stephen HillChief Operating Officer$2,251,930

Board service

Lyell Immunopharma board · FY2021–FY2025
Director compensation in US dollars, as Lyell Immunopharma reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$85,000$0$37,609$0$122,609
FY2024$82,734$0$205,335$0$288,069
FY2023$80,000—$230,745—$310,745
FY2022$80,000—$249,223—$329,223
FY2021—————

Each year as the company reported it in Lyell Immunopharma's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Lyell Immunopharma pays directors a $50,000 cash retainer and $300,000 in Options. As stated in Lyell Immunopharma's FY2025 proxy.

The full Lyell Immunopharma compensation record

free company brief

This page is one person within Lyell Immunopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lyell Immunopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Richard Klausner's compensation dossier · One-time report. No refunds.